eMed CEO resigns

Article

In a move that took the PACS industry by surprise, eMed Technologies announced May 17 the resignation of CEO Caren Mason. The company cited Mason’s long-distance commute from Wisconsin to eMed’s Boston-based headquarters and her

In a move that took the PACS industry by surprise, eMed Technologies announced May 17 the resignation of CEO Caren Mason. The company cited Mason’s long-distance commute from Wisconsin to eMed’s Boston-based headquarters and her responsibilities to family as reasons for her resignation. Since taking the helm in January 2000, Mason led eMed to an improved position within the PACS and networking marketplace. She also bolstered corporate finances by securing $22 million dollars in venture capital investment. The company’s board of directors has initiated a search for Mason’s replacement.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.